ピルフェニドン治療は,自己相性多囊性腎疾患における線維症を弱める
bioRxiv : the preprint server for biology
|September 5, 2025
まとめ
ピルフェニドンは腎臓線維症を軽減し,自己相性多囊性腎臓病 (ADPKD) の腎臓構造を保ちます. この抗線維薬はADPKDの進行を遅らせ,腎臓の機能を改善する可能性がある.
科学分野:
- 腎臓科
- 繊維症の研究
- 薬理学について
背景:
- 自体主有多囊性腎臓病 (ADPKD) は,キスト形成,線維症,炎症を含み,しばしば腎不全につながる.
- ADPKDにおける腎臓線維症は,ミオフィブロブラストの活性化と細胞外マトリックス (ECM) の過剰な堆積によって引き起こされ,疾患の進行を加速します.
研究 の 目的:
- ミオフィブロブラストの活動,ECMの生成,ADPKDの進行を緩和する抗線維薬であるピルフェニドンの治療の可能性を調査する.
- ADPKDの臨床前モデルにおいて,ピルフェニドンが線維症と腎機能に及ぼす影響を評価する.
主な方法:
- 主要なヒトのADPKDミオフィブロブラストは,増殖,移動,収縮,およびECMの生成を評価するために,ピルフェニドンでインビトロで治療した.
- ADPKDのPkd1RC/ RCマウスモデルは,ピルフェニドンがキストの成長,線維症,腎機能に及ぼすインビボ効果を評価するために使用された.
主要な成果:
- ピルフェニドン治療は,ECMの遺伝子発現,ミオフィブロブラストの増殖,移動,収縮性をインビトロで低下させた.
- 生体内では,ピルフェニドンは腎繊維症,コラーゲン収縮,ミオフィブロブラストの蓄積,およびプロフィブロティックシグナル伝達経路 (TGF-β/ SMAD3,mTOR) を減少させた.
- ピルフェニドンは腎臓のサイズとキストの面積を減少させ,ADPKDのマウスの腎臓の形態と機能を改善したが,キストの数は変化しなかった.
結論:
- ピルフェニドンは腎繊維症を効果的に軽減し,ADPKDでは腎臓の構造を保ちます.
- これらの発見は,ADPKDにおける線維症を標的とした治療戦略としてピルフェニドンの可能性を裏付ける.
さらに関連する動画
08:46Implementing Patch Clamp and Live Fluorescence Microscopy to Monitor Functional Properties of Freshly Isolated PKD Epithelium
Published on: September 1, 2015
9.9K
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
538
関連する概念動画
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
250
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
250
01:24Cystic Fibrosis: Management
220
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
220
01:11Renal Failure: Dose Adjustments
151
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
151
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
223
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
223
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
246
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
246
01:28Chronic Kidney Disease III: Interprofessional Care
77
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
77